NZ767378A - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents
Dosage forms and methods for enantiomerically enriched or pure bupropionInfo
- Publication number
- NZ767378A NZ767378A NZ767378A NZ76737819A NZ767378A NZ 767378 A NZ767378 A NZ 767378A NZ 767378 A NZ767378 A NZ 767378A NZ 76737819 A NZ76737819 A NZ 76737819A NZ 767378 A NZ767378 A NZ 767378A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dosage forms
- bupropion
- methods
- enantiomerically enriched
- pure bupropion
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title 1
- 229960001058 bupropion Drugs 0.000 title 1
- SNPPWIUOZRMYNY-VIFPVBQESA-N (S)-bupropion Chemical compound CC(C)(C)N[C@@H](C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-VIFPVBQESA-N 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862634718P | 2018-02-23 | 2018-02-23 | |
US201962794469P | 2019-01-18 | 2019-01-18 | |
US201962809480P | 2019-02-22 | 2019-02-22 | |
PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ767378A true NZ767378A (en) | 2024-03-22 |
Family
ID=67688503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ767378A NZ767378A (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP3755312A4 (es) |
JP (3) | JP2021513998A (es) |
KR (2) | KR20230075531A (es) |
CN (1) | CN112087999A (es) |
AU (2) | AU2019223187B2 (es) |
BR (1) | BR112020017179A2 (es) |
CA (1) | CA3092076A1 (es) |
CL (1) | CL2020002166A1 (es) |
CR (1) | CR20200415A (es) |
EC (1) | ECSP20060179A (es) |
IL (1) | IL276871A (es) |
MA (1) | MA51914A (es) |
MX (2) | MX2020008704A (es) |
NI (1) | NI202000056A (es) |
NZ (1) | NZ767378A (es) |
PE (1) | PE20211752A1 (es) |
SG (1) | SG11202008056SA (es) |
WO (1) | WO2019165379A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
AU2020349419B2 (en) * | 2019-09-20 | 2023-11-02 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999038502A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
PL196544B1 (pl) * | 2003-08-08 | 2008-01-31 | Biovail Lab Int Srl | Tabletka o zmodyfikowanym uwalnianiu |
WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
-
2019
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active IP Right Cessation
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko active Application Filing
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-08-23 IL IL276871A patent/IL276871A/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521A1/en active Pending
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3755312A4 (en) | 2022-03-16 |
IL276871A (en) | 2020-10-29 |
NI202000056A (es) | 2021-01-11 |
KR20210003091A (ko) | 2021-01-11 |
PE20211752A1 (es) | 2021-09-06 |
AU2022204521A1 (en) | 2022-07-21 |
AU2019223187B2 (en) | 2022-07-28 |
ECSP20060179A (es) | 2020-12-31 |
CR20200415A (es) | 2021-02-03 |
CN112087999A (zh) | 2020-12-15 |
JP2022153638A (ja) | 2022-10-12 |
EP3755312A1 (en) | 2020-12-30 |
KR20230075531A (ko) | 2023-05-31 |
JP2021513998A (ja) | 2021-06-03 |
JP2024075655A (ja) | 2024-06-04 |
CL2020002166A1 (es) | 2020-10-23 |
WO2019165379A1 (en) | 2019-08-29 |
MX2020008704A (es) | 2020-12-07 |
MX2023009281A (es) | 2023-08-17 |
CA3092076A1 (en) | 2019-08-29 |
MA51914A (fr) | 2020-12-30 |
SG11202008056SA (en) | 2020-09-29 |
AU2019223187A1 (en) | 2020-09-17 |
BR112020017179A2 (pt) | 2020-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ767378A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
HUP0204023A2 (hu) | Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
HUP0103408A2 (hu) | Dopamin-újrafelvétel inhibitorokat tartalmazó kompozíciók és az inhibitorok alkalmazási eljárásai | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
MX2021008247A (es) | Combinacion de dextrometorfano y bupropion para el tratamiento de depresion. | |
PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
HUP0401867A2 (hu) | A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére | |
MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
MX2021002321A (es) | Nuevos metodos. | |
MX2021005967A (es) | Formas purificadas de rofecoxib, métodos de fabricación y uso. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
MX2021008536A (es) | Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa. | |
MX2021007142A (es) | Compuestos organicos. | |
JP2016505050A5 (es) | ||
NZ751972A (en) | Treatment of prurigo nodularis | |
MY193963A (en) | Composition for treating joint diseases and kit containing same | |
CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
MX2023006720A (es) | Tratamiento con ciclobenzaprina para fibromialgia. | |
MX2023005462A (es) | Compuestos macrociclicos y metodos para usarlos. | |
MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
MX2022012693A (es) | Composicion que comprende metilfolato. |